Key Highlights
- PROCEPT BioRobotics shares were trading up 12.10% at $22.61, against a prior close of $20.17.
- Third-quarter results are due after the close today.
- Analysts expect a loss of about $0.39 per share on Revenue near $100.7 million.
- The stock trades above the mean analyst target of about $22.25.
- A securities class action over a discount program remains an overhang.
Risk-On Tape Lifts the Stock Ahead of the Report
PROCEPT BioRobotics (NASDAQ:PRCT) shares were trading up 12.10% at $22.61 on Wednesday, ahead of third-quarter results due after the close. A broad rally in health stocks after Democratic midterm wins helped, and the shares now sit above the mean analyst target of about $22.25 and well above the 52-week low of $16.67.
Consensus calls for a loss of about $0.39 per share on revenue near $100.7 million, roughly 27% growth.
Aquablation Is the Growth Engine
The San Jose company makes the Aquablation therapy, an image-guided, heat-free robotic waterjet procedure for removing prostate tissue in benign prostatic hyperplasia. It sells through an installed-base model, with hospitals and surgery centers buying the system and Recurring Revenue coming from single-use handpieces and service contracts. Trailing revenue is about $337 million.
The company is still unprofitable and is pursuing clinical expansion, including the WATER IV prostate cancer studies.
Legal and Competitive Overhangs
Investors are watching a securities class action alleging that a discount program inflated handpiece sales. Competition is also building in urology, with Medtronic (NYSE:MDT) selling the Hugo robot and Johnson & Johnson (NYSE:JNJ) offering the Monarch platform.
Analyst sentiment is mixed, with a consensus rating of Hold.
What to Watch in the Print
Procedure growth, handpiece utilization, the pace of system placements and any update on the lawsuit are the likely focus. A stock that has run into the report needs a clean quarter and firm guidance to extend the move.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...